Market Challenges And Opportunities

Fibrosarcoma Drugs Market Driver

Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the forecast period. Fibrosarcoma being malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence, which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017, received US FDA approval for investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication are expected to boost growth of the fibrosarcoma drugs market over the forecast period.

Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs market. Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with less side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market. Key players as well as government organization such as Nation Cancer Institute or American Society of Clinical Oncology sponsors or collaborate for the development of novel therapies and drugs. For instance, Bayer partners with loxo oncology to develop and commercialise cancer therapies. Furthermore, Bristol-Myers Squibb Company acquired IFM therapeutics, 2017, to acquire right on preclinical stimulator of interferon genes (STING) and NLRP3 agonist programs, which are focused on enhancing the innate immune response for tumour.